Publications
152
Citations
4,308
Est. group size
~16
Recurring co-author estimate
Active years
31
Publishing since 1996
Typically publishes in teams of ~12 · 10% small-team papers (≤3 authors) · across 44 venues
- Longitudinal and stability-aware analysis reveals treatment-specific microRNA response signatures following immune-reconstitution and B-cell-targeted therapies in multiple sclerosis
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis
Advances in Therapy · 2026
- Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis
International Journal of Molecular Sciences · 2026
- Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension (P7-19.003)
Neurology · 2026
- Smoking accelerates immunosenescence in multiple sclerosis
Frontiers in Immunology · 2026
- Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis
Journal of Biological Chemistry · 2025
- Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Neurology · 2025
- Comorbidities Are Associated With Unfavorable Outcome in Aquaporin‐4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease: Exploratory Study From the <scp>CROCTINO</scp> Cohort
European Journal of Neurology · 2025
- Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series
Journal of Neuroimmunology · 2025
- Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study
Multiple Sclerosis Journal · 2025
- The Impact of Multiple Sclerosis on Work Productivity: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis
NeuroSci · 2025
- A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Annals of Clinical and Translational Neurology · 2025
- Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial
JCI Insight · 2025
- Effectiveness and Outcome Predictors of Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (S38.004)
Neurology · 2025
- Efficacité comparative et risques d’infection sévère (IS) chez les patients adultes atteints de sclérose en plaques (PwMS) traités par diroximel fumarate (DRF) ou anticorps monoclonaux anti-CD20 : analyse de données de soins/remboursements en vie réelle
Revue Neurologique · 2025
- Neurology×26
- Multiple Sclerosis and Related Disorders×7
- Neurology Neuroimmunology & Neuroinflammation×6
- Multiple Sclerosis Journal×5
- JCI Insight×5
- Qiuming Zeng
Medicine · The Ohio State University
- Tirisham Gyang
Medicine · The Ohio State University
- Jennifer C. Hayes
Medicine · University of Michigan
- Yuji Tomizawa
Medicine · The Ohio State University
- Michael K. Racke
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile